Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC

Journal of Cellular and Molecular Medicine

Volumn 18, Issue 8, 2014, Pages 1519-1539

  Paz Ares, Luis ^a   Soulières, Denis ^b   Moecks, Joachim ^c   Bara, Ilze ^d   Mok, Tony ^e   Klughammer, Barbara ^d  

^a CSIC   (Spain)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c BIOMCON GmbH   (Germany)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Afatinib; Epidermal growth factor receptor (EGFR); Erlotinib; First line; Gefitinib; Icotinib; Mutation; Non small cell lung cancer (NSCLC); Tyrosine kinase inhibitor

Indexed keywords

EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR;

CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; HUMAN; LITERATURE; LUNG NEOPLASMS; META ANALYSIS (TOPIC); MORTALITY; MUTATION; PROGNOSIS; SURVIVAL RATE;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; META-ANALYSIS AS TOPIC; MUTATION; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVIEW LITERATURE AS TOPIC; SURVIVAL RATE;

EID: 84912575628     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12278     Document Type: Article

References (119)

1. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353: 123-32.
2. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010; 11: 521-9.
3. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutationpositive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, openlabel, randomised, phase 3 study. Lancet Oncol. 2011; 12: 735-42.
4. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13: 239-46.
5. Mok T, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361: 947-57.
6. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol. 2006; 24: 5034-42.
7. Douillard JY, Shepherd FA, Hirsh V, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol. 2010; 28: 744-52.
8. Paz-Ares L, Soulieres D, Melezinek I, et al. Clinical outcomes in non-small cell lung cancer patients with EGFR mutations: pooled analysis. J Cell Mol Med. 2010; 14: 51-69.
9. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010; 11: 121-8.
10. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for nonsmall cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362: 2380-8.
11. Yang JC-H, Schuler MH, Yamamoto N, et al. LUX-Lung 3: a randomized, openlabel, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol. 2012; 30: LBA7500.
12. Mok T, Spigel DR, Park K, et al. Efficacy and safety of PF299804 as first-line treatment (tx) of patients (pts) with advanced (adv) NSCLC selected for activating mutation (mu) of epidermal growth factor receptor (EGFR). Ann Oncol. 2010; 21: LBA18.
13. Boyer MJ, Blackhall FH, Park K, et al. Efficacy and safety of PF299804 versus erlotinib (E): a global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT). J Clin Oncol. 2010; 28: LBA7523.
14. Ou S-H. Second generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence. Crit Rev Oncol Hematol. 2012; 83: 407-21.
15. Sun Y, Shi Y, Zhang L, et al. A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN). J Clin Oncol. 2011; 29: Abstract 7522.
16. Ren GJ, Zhao YY, Zhu YJ, et al. Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in nonsmall cell lung cancer. Chin Med J. 2011; 124: 19-25.
17. Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nature Rev Cancer. 2007; 7: 169-81.
18. Gaughan EM, Costa DB. Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. Ther Adv Med Oncol. 2011; 3: 113-25.
19. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129-39.
20. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304: 1497-500.
21. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumours to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004; 101: 13306-11.
22. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Nat Cancer Inst. 2005; 97: 339-46.
23. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 2004; 64: 8919-23.
24. Sequist LV, Bell DW, Lynch TJ, et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol. 2007; 25: 587-95.
25. Riely GJ, Politi KA, Miller VA, et al. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res. 2006; 12: 7232-41.
26. Peters S, Adjei AA, Gridelli C, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012; 23: vii56-64.
27. Hotta K, Matsuo K, Ueoka H, et al. Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol. 2004; 22: 3860-7.
28. Smouse JH, Cibas ES, Janne PA, et al. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer Cytopathol. 2009; 117: 67-72.
29. Gately K, O'Flaherty J, Cappuzzo F, et al. The role of molecular footprint of EGFR in tailoring treatment decisions in NSCLC. J Clin Pathol. 2012; 65: 1-7.
30. Hesterberg T, Monaghan S, Moore DS, et al. Bootstrap methods and permutation tests. Companion chapter 18. In: Moore D, McCabe G, Duckworth WM, Alwan LC, editors. The practice of business statistics. 2nd ed. New York: W.H. Freeman and Co; 2009. pp. 18-3-74.
31. Ahn MJ, Park BB, Ahn JS, et al. Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced nonsmall cell lung cancer? Clin Cancer Res. 2008; 14: 3860-6.
32. Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced nonsmall-cell lung cancer. J Clin Oncol. 2007; 25: 760-6.
33. Jackman DM, Cioffredi L, Lindeman NI, et al. Phase II trial of erlotinib in chemotherapy-naive women with advanced pulmonary adenocarcinoma. J Clin Oncol. 2009; 27: 423s.
34. Miller VA, Riely GJ, Zakowski MF, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol. 2008; 26: 1472-8.
35. Pirker R, Minar W, Filipits M. Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed nonsmall-cell lung cancer. Clin Lung Cancer. 2008; 9: S109-15.
36. Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2006; 12: 839-44.
37. Rosell R, Perez-Roca L, Sanchez JJ, et al. Customized treatment in non-smallcell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS ONE. 2009; 4: e5133.
38. Zhou S, Ren S, Yan L, et al. Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer. Respirology. 2009; 14: 709-15.
39. Amann JM, Lee JW, Roder H, et al. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. J Thorac Oncol. 2010; 5: 169-78.
40. Ciuleanu T, Stelmakh S, Cicenas S, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. 2012; 13: 300-8.
41. Choi DR, Lee DH, Choi CM, et al. Erlotinib in first-line therapy for non-small cell lung cancer: a prospective phase II study. Anticancer Res. 2011; 31: 3457-62.
42. De Greve J, Van Meerbeeck JP, Vansteenkiste J, et al. First-line erlotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) carrying an activating EGFR mutation: a multicentre academic phase II study in Belgium. J Thorac Oncol. 2011; 6: S1270 (P3.158).
43. Fiala O, Pesek M, Krejci J, et al. Chemotherapy versus erlotinib in the second line treatment of advanced nonsmall cell lung cancer. J Thorac Oncol. 2011; 6: S1259.
44. Rosell R, Gervais R, Vergnenegre A, et al. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: interim results of the European Erlotinib versus Chemotherapy (EURTAC) phase III randomized trial. J Thorac Oncol. 2011; 6: S314.
45. Janne PA, Wang X, Socinski MA, et al. Outcome of advanced NSCLC patients with EGFR exon 19 and 21 mutations treated with erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in CALGB 30406. J Thorac Oncol. 2011; 6: S447.
46. Lynch TJ, Fenton D, Hirsh V, et al. A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer. J Thorac Oncol. 2009; 4: 1002-9.
47. Okano Y, Shinohara T, Machida H, et al. Phase II trial of erlotinib in previously treated patients with non-small cell lung cancer. J Thorac Oncol. 2011; 6: S1175.
48. Pallis AG, Voutsina A, Kentepozidis N, et al. A phase II trial of erlotinib as frontline treatment in clinically selected patients with non-small-cell lung cancer. Clin Lung Cancer. 2012; 13: 129-35.
49. Puente J, Gonzalez Larriba JL, Gajate P, et al. Clinical impact of the feasibility of epidermal growth factor receptor (EGFR) mutations detection in cytological samples of patients (pt) with non-small cell lung cancer (NSCLC) treated with erlotinib (E) at first line. J Clin Oncol. 2011; 29: Abstract e18051.
50. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009; 361: 958-67.
51. Rotella V, Mazzoni F, Pratesi N, et al. Erlotinib as a second-line therapy in advanced non small cell lung cancer: correlation between clinical characteristics and biomarkers. Eur J Cancer Suppl. 2009; 7: 545.
52. Spigel DR, Burris HA 3rd, Greco FA, et al. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2011; 29: 2582-9.
53. Sun J-M, Won Y-W, Kim ST, et al. The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients. J Cancer Res Clin Oncol. 2011; 134: 687-94.
54. Takahashi T, Yamamoto N, Nukiwa T, et al. Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer. Anticancer Res. 2010; 30: 557-63.
55. Zhu YJ, Xia Y, Ren GJ, et al. Efficacy and clinical/molecular predictors of erlotinib monotherapy for Chinese advanced nonsmall cell lung cancer. Chin Med J. 2010; 123: 3200-5.
56. Asahina H, Yamazaki K, Kinoshita I, et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer. 2006; 95: 998-1004.
57. Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in non-smallcell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol. 2005; 23: 8081-92.
58. Buckingham LE, Coon JS, Morrison LE, et al. The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib. J Thorac Oncol. 2007; 2: 414-22.
59. Chou TY, Chiu CH, Li LH, et al. Mutation in the tyrosine-kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res. 2005; 11: 3750-7.
60. Cortes-Funes H, Gomez C, Rosell R, et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib treated nonsmall-cell lung cancer patients. Ann Oncol. 2005; 16: 1081-6.
61. D'Addario G, Rauch D, Stupp R, et al. Multicenter phase II trial of gefitinib firstline therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Ann Oncol. 2008; 19: 739-45.
62. Dongiovanni D, Daniele L, Barone C, et al. Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)? Lung Cancer. 2008; 61: 73-81.
63. Fukuoka M, Wu Y, Thongprasert S, et al. Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS). J Clin Oncol. 2009; 27: 408s.
64. Han SW, Kim TY, Lee KH, et al. Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated nonsmall-cell lung cancer patients. Lung Cancer. 2006; 54: 201-7.
65. Hirsch FR, Varella-Garcia M, Cappuzzo F, et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol. 2007; 18: 752-60.
66. Ichihara S, Toyooka S, Fujiwara Y, et al. The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int J Cancer. 2007; 120: 1239-47.
67. Inoue A, Kobayashi K, Usui K, et al. Firstline gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 2009; 27: 1394-400.
68. Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol. 2006; 24: 3340-6.
69. Kim KS, Jeong JY, Kim YC, et al. Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin Cancer Res. 2005; 11: 2244-51.
70. Kimura H, Suminoe M, Kasahara K, et al. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer. 2007; 97: 778-84.
71. Kobayashi K, Inoue A, Usui K, et al. Firstline gefitinib for poor PS patients with EGFR mutations. J Clin Oncol. 2008; 26: 8070s.
72. Koyama N, Jinn Y, Takabe K, et al. The characterization of gefitinib sensitivity and adverse events in patients with non-smallcell lung cancer. Anticancer Res. 2006; 26: 4519-25.
73. Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine-kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res. 2007; 13: 2890-6.
74. Oshita F, Matsukuma S, Yoshihara M, et al. Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer. Br J Cancer. 2006; 95: 1070-5.
75. Pallis AG, Voutsina A, Kalikaki A, et al. 'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. Br J Cancer. 2007; 97: 1560-6.
76. Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harbouring somatic EGFR mutations. J Clin Oncol. 2008; 26: 2442-9.
77. Shao Y, Lin Z, Hu F, et al. Quality of life in advanced non-small cell lung cancer patients receiving first-line gefitinib monotherapy. J Clin Oncol. 2009; 27: 511s.
78. Shoji F, Yano T, Yoshino I, et al. The characteristics and failure pattern of gefitinib responders with postoperative recurrence of pulmonary adenocarcinoma. Eur J Surg Oncol. 2008; 34: 89-93.
79. Sugio K, Uramoto H, Onitsuka T, et al. Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations. Lung Cancer. 2009; 64: 314-8.
80. Sunaga N, Tomizawa Y, Yanagitani N, et al. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer. 2007; 56: 383-9.
81. Sutani A, Nagai Y, Udagawa K, et al. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer. 2006; 95: 1483-9.
82. Takano T, Ohe Y, Tsuta K, et al. Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib. Clin Cancer Res. 2007; 13: 5385-90.
83. Tamura K, Okamoto I, Kashii T, et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Thoracic Oncology Group trial (WJTOG0403). Br J Cancer. 2008; 98: 907-14.
84. Varella-Garcia M, Mitsudomi T, Yatabe Y, et al. EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort. J Thorac Oncol. 2009; 4: 318-25.
85. Xu JM, Han Y, Duan HQ, et al. EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced nonsmall cell lung cancer patients treated with gefitinib. J Cancer Res Clin Oncol. 2009; 135: 771-82.
86. Zhang XT, Li LY, Mu XL, et al. The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. Ann Oncol. 2005; 16: 1334-42.
87. Asami K, Koizumi T, Hirai K, et al. Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study. Clin Lung Cancer. 2011; 12: 387-92.
88. Azuma K, Okamoto I, Kawahara A, et al. Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment. J Thorac Oncol. 2012; 7: 122-7.
89. Chen X, Li W, Hu X, et al. Effect of gefitinib challenge to initial treatment with nonsmall cell lung cancer. Biomed Pharmacother. 2011; 65: 542-6.
90. Chen YM, Fan WC, Tsai CM, et al. A phase II randomized trial of gefitinib alone or with tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy. J Thorac Oncol. 2011; 6: 1110-6.
91. Giovannetti E, Zucali PA, Peters GJ, et al. Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib. Mol Cancer Ther. 2010; 9: 581-93.
92. Inoue Y, Minegishi Y, Maemondo S, et al. A final results of a phase II study of firstline gefitinib for elderly patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations; NEJ 003 study. Ann Oncol. 2010; 21: viii141.
93. Lee JS, Park K, Kim S-W, et al. A randomized phase III study of gefitinib (IRESSATM) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. J Thorac Oncol. 2009; 4: S283 (PRS.4).
94. Kim DW, Lee S-H, Lee JS, et al. A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations. Lung Cancer. 2011; 71: 65-9.
95. Masago K, Fujia S, Togashi Y, et al. Clinicopathologic factors affecting the progression-free survival of patients with advanced non-small-cell lung cancer after gefitinib therapy. Clin Lung Cancer. 2011; 12: 56-61.
96. Moiseyenko VM, Procenko SA, Levchenko EV, et al. High efficacy of first-line gefitinib in non-Asian patients with EGFR-mutated lung adenocarcinoma. Onkologie. 2010; 33: 231-8.
97. Park SH, Ha SY, Lee JI, et al. Epidermal growth factor receptor mutations and the clinical outcome in male smokers with squamous cell carcinoma of lung. J Korean Med Sci. 2009; 24: 448-52.
98. Uruga H, Kishi K, Fujii T, et al. Efficacy of gefitinib for elderly patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor gene mutations: a retrospective analysis. Intern Med. 2010; 49: 103-7.
99. Wu J-Y, Shih J-Y, Chen K-Y, et al. Gefitinib therapy in patients with advanced nonsmall cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations. Medicine. 2011; 90: 159-67.
100. Wu Y-L, Zhou C, Chen G, et al. First biomarker analyses from a phase III, randomised, open-label, first-line study of erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese patients (pts) with advanced non-small-cell lung cancer (NSCLC) with EGFR activating mutations (OPTIMAL, CTONG 0802). Ann Oncol. 2010; 21: viii6.
101. Yamaguchi H, Soda H, Nakamura Y. Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2011; 67: 331-8.
102. Yoshida K, Yatabe Y, Park J, et al. Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations. J Cancer Res Clin Oncol. 2010; 136: 527-35.
103. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with nonsmall-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005; 23: 5900-9.
104. Lee KH, Han SW, Hwang PG, et al. Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer. Jpn J Clin Oncol. 2006; 36: 344-50.
105. Tambo Y, Kasahara K, Sone T, et al. Prognostic and predictive impact of EGFR and K-ras mutation, and EGFR gene copy number in patients with advanced non-small cell lung cancer (NSCLC) who received first-line cytotoxic chemotherapy. J Clin Oncol. 2009; 27: 430s.
106. Kalikaki A, Koutsopoulos A, Hatzidaki D, et al. Clinical outcome of patients with non-small cell lung cancer receiving frontline chemotherapy according to EGFR and K-RAS mutation status. Lung Cancer. 2010; 69: 110-5.
107. Kim HR, Shim HS, Chung JH, et al. Distinct clinical features and outcomes in never-smokers with non-small cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer. 2012; 118: 729-39.
108. Lin C-C, Hsu H-H, Sun C-T, et al. Chemotherapy response in East Asian non-small cell lung cancer patients harboring wildtype or activating mutation of epidermal growth factor receptors. J Thorac Oncol. 2010; 9: 1424-9.
109. Matsumoto S, Touge H, Kodani M. The difference in chemotherapeutic efficacy between advanced non-small cell lung cancers with and without EGFR mutations. J Thorac Oncol. 2011; 6: S1230.
110. Yang JC-H, Shih J-Y, Su W-C, et al. A phase ii study of afatinib (BIBW 2992) in patients with adenocarcinoma of the lung and activating EGFR/HER1 Mutations (LUXLung 2). J Thorac Oncol. 2010; 5: S376-7.
111. Rosell R, Massuti Sureda B, Costa C, et al. Concomitant actionable mutations and overall survival (OS) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) included in the EURTAC trial: EGFR L858R, EGFR T790M, TP53 R273H and EML4-ALK (V3). Ann Oncol. 2012; 23: ixe22 (LBA31).
112. Douillard JY, Ostoros G, Cobo M, et al. Efficacy, safety and tolerability results from a phase IV, open-label, single arm study of 1stline gefitinib in Caucasian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Lung Cancer. 2013; 80: S31.
113. Ramalingam SS, Blackhall F, Krzakowski M, et al. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2012; 30: 3337-44.
114. Han JY, Park K, Kim SW, et al. First-SIGNAL: first-line single-agent Iressa versus gemcitabine and cisplatin trial in neversmokers with adenocarcinoma of the lung. J Clin Oncol. 2012; 30: 1122-8.
115. De Pas T, Toffalorio F, Manzotti M, et al. Activity of epidermal growth factor receptortyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations. J Thorac Oncol. 2011; 6: 1895-901.
116. Klughammer B, Spleiss O. 'Other' (nonactivating, non-T790M) EGFR mutations and their clinical implications collected from various Tarceva trials in NSCLC. Eur J Cancer. 2011; 47: S20-1.
117. Jackman DM, Yeap BY, Sequist LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006; 12: 3908-14.
118. Wu M, Zhao J, Song SW, et al. EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer. Lung Cancer. 2010; 67: 343-7.
119. Mok T, Wu YL, Thongprasert S, et al. A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/ platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II. J Clin Oncol. 2012; 30: Abstract 7519.